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Hydroxyurea is used for sickle-cell disease patients in order to in-
crease fetal hemoglobin synthesis and consequently decrease the
severity of pain episodes. Fetal hemoglobin, which is formed by γ-
globin chains A and G, is present in a constant composition through-
out fetal development: about 75% of Gγ and 25% of Aγ. In contrast,
adult red cells contain about 40% of Gγ and 60% of Aγ. In the present
study, we analyzed the effect of hydroxyurea induction on the γ chain
composition of fetal hemoglobin in 31 sickle-cell disease patients
treated with hydroxyurea. The control group was composed of 30
sickle-cell disease patients not treated with hydroxyurea in clinical
steady state. The patients were older than 13 years and were not
matched for age. All patients were seen at Hemocentro/UNICAMP
and Boldrini Infantile Center, Campinas, SP, Brazil. The levels of total
hemoglobin were significantly higher in patients treated with hy-
droxyurea (mean ± SD, 9.6 ± 2.16 g/dl) than in untreated patients
(8.07 ± 0.91 g/dl). Fetal hemoglobin levels were also higher in treated
patients (14.16 ± 8.31%) than in untreated patients (8.8 ± 4.09%), as
was the Gγ/Aγ ratio (1.45 ± 0.78 vs 0.98 ± 0.4, P < 0.005). The increase
in the Gγ/Aγ ratio in patients treated with hydroxyurea suggests the
prevalence of a pattern of fetal hemoglobin synthesis, whereas pa-
tients not treated with hydroxyurea maintain the adult pattern of fetal
hemoglobin synthesis. Because no correlation was observed between
the Gγ/Aγ ratio and total hemoglobin or fetal hemoglobin levels, the
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Fetal hemoglobin (HbF) interferes with
the intracellular polymerization of sickle he-
moglobin and has beneficial effects on pa-
tients with sickle-cell disease (SCD) (1). On
this base, several agents such as 5-azacytidine
and hydroxyurea (HU), which are known to
stimulate HbF synthesis, have been used in
SCD patients to decrease the frequency and
severity of pain episodes (2,3).
Previous studies showed that approxi-
mately 60% of the patients treated with HU
responded with an increased HbF level and a
reduction (44%) in the annual rate of painful
episodes. There was also a significant varia-
tion in the ability of patients to respond to
HU. Prolonged treatment is generally re-
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quired to obtain the clinical response (4,5).
HbF is formed by γ-globin chain A or G
according to the amino acid at the 136 posi-
tion in the γ chain, i.e., alanine or glycine. The
proportion of Gγ to Aγ is constant throughout
fetal development: about 75% of Gγ and 25%
of Aγ. However, in adult red cells, the small
amount of HbF is composed mainly of Aγ
(60% vs 40% of Gγ) (6).
Sickle-cell anemia patients present dif-
ferent levels of HbF and a relation of HbF
and Gγ levels with the ßS haplotypes has been
demonstrated. Senegal and Benin haplotypes
differed in Gγ expression, mean percentage
of HbF, which was higher in the Senegal
than in the Benin type, while the Bantu
haplotype had intermediate features (7). More
recently, mRNA analysis strengthened these
data. Sickle-cell anemia patients with Senegal
and Saudi Arabia-India haplotypes had higher
percentages of γ mRNA than Benin, Bantu
or Cameroon types (8).
Various in vitro cell culture systems have
been used to study the effects of HbF-induc-
ing agents on γ-globin chain gene expression
(9,10). Xu and Zimmer (11) demonstrated
the selective increase of Gγ mRNA levels in
K562 cells treated with HU. Understanding
the mechanisms by which HU differentially
regulates HbF gene expression during devel-
opment may provide data about the mechan-
isms of action of the pharmacological agents
used in SCD.
In the present study, we have determined
the effect of HU induction on total Hb level,
HbF level and mainly the Gγ/Aγ ratio. In
addition, we have compared the relationship
between these parameters in order to estab-
lish the HbF synthesis patterns in patients
with and without HU.
HbF level was determined by the alkaline
pH denaturation method (12). In order to
separate gel Gγ and Aγ, HbF was precipitated
with sulfosalicylic acid and globin chains
were analyzed by polyacrylamide gel elec-
trophoresis, followed by densitometry to
determine the proportions of the two chains
(13,14). Patients with SCD at Hemocentro/
UNICAMP and Boldrini Infantile Center,
Campinas, SP, Brazil, treated with HU (group
1, N = 31) were compared with a control
group of SCD patients without HU (group 2,
N = 30). Control patients were free of crises.
All patients but two were older than 13
years. The duration of treatment ranged from
2 months to 5 years (mean time, 2 years).
Group 1 patients had significantly higher
levels of Hb, HbF, and Gγ/Aγ ratio than
group 2 (Mann-Whitney test; Table 1).
No correlation was found between total
Table 2. Correlation between the variables stud-
ied in sickle-cell disease (SCD) patients treated
with hydroxyurea (HU) (group 1) and in SCD pa-
tients not treated with HU (group 2).
Group 1 Group 2
Hb and HbF r: 0.24632 r: 0.44291
P: 0.1816 P: 0.0142
HbF and Gγ/Aγ r: -0.17769 r: -0.22209
P: 0.3389 P: 0.2382
Hb and Gγ/Aγ r: -0.19738 r: -0.37086
P: 0.2872 P: 0.0436
Hb (g/dl) = hemoglobin; HbF (%) = fetal hemoglo-
bin.
Table 1. Hemoglobin, fetal hemoglobin and Gγ/Aγ
ratio in sickle-cell disease (SCD) patients treated
with hydroxyurea (HU) (group 1) and in SCD pa-
tients not treated with HU (group 2).
Variable Mean ± SD Median Range
Hemoglobin (g/dl)
Group 1 9.6 ± 2.16* 9.5 5.3-16.2
Group 2 8.07 ± 0.91 8.05 6.6-11.1
Fetal hemoglobin (%)
Group 1 14.16 ± 8.31* 12.4 1.0-30.8
Group 2 8.8 ± 4.09 8.4 2.9-19.8
Gγ/Aγ
Group1 1.45 ± 0.78* 1.17 0.48-3.25
Group 2 0.98 ± 0.4 0.87 0.47-1.94
Group 1: N = 31; group 2: N = 30. *P < 0.05
compared to patients not treated with HU (Mann-
Whitney test).
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Hb and HbF levels or between Hb levels
(total and HbF) and Gγ/Aγ ratio in group 1.
However, there was a positive correlation
between Hb level and HbF level and a nega-
tive correlation between Hb level and Gγ/Aγ
ratio in group 2 (Table 2).
Several possible mechanisms have been
suggested to explain the action of HU on
HbF synthesis. One of them is that HU selec-
tively increases HbF production because,
like 5-azacytidine, it may act directly on late
erythroid progenitors, reprogramming them
to produce more HbF (10,15). An in vitro
study has shown that the number of burst-
forming unit-erythroid colonies decreased
whereas HbF levels increased in the pres-
ence of HU (16).
The present results, which are in agree-
ment with other studies (2,3,5), demonstrate
that treatment with HU increases HbF levels
in patients with SCD. In addition, the pre-
dominant effect of HU on Gγ synthesis was
evident since the Gγ/Aγ ratio was significant-
ly higher in the group treated with HU than
in the control group. Similar results were
reported by Xu and Zimmer (11) using cell
culture: the Gγ mRNA level increased 2- to
3-fold at 168 h, whereas the Aγ mRNA level
did not change.
The lack of correlation between HbF lev-
els and Gγ/Aγ ratio suggests that the return to
the fetal γ chain synthesis does not imply an
absolute increase of HbF production. There
is a wide range of factors, both genetic and
acquired, that interfere with the increase in
HbF production. Among these factors, HbF
production can be influenced by cis-acting
determinants such as ß-globin haplotype and
by trans-acting elements such as the X-linked
“F cell” production locus. It was demon-
strated that the “F cell” production locus is a
more important factor in determining HbF
levels than ß-globin haplotype, α-globin gene
number, or patient age or sex (17). A pla-
cebo-controlled study of the efficacy of HU
therapy in sickle-cell anemia patients showed
that the Central African Republic (CAR)
haplotype was associated with a reduced
HbF production response, while patients with
the highest baseline granulocyte and reticu-
locyte counts had the greatest increase in
HbF. These data indicate that bone marrow
reserve may be an important factor in HbF
response. The maintenance of the prolifera-
tive capacity of bone marrow in spite of the
myelotoxic effects of the drugs is important
to sustain HbF increases during HU treat-
ment (18).
In the present study it was not possible to
correlate γ chain production and composi-
tion with ß-globin haplotypes since haplo-
types were determined in 26 of 31 treated
patients and only in 10 of 30 controls. How-
ever, haplotype distribution was similar for
the two groups and was divided into Benin
and CAR haplotypes according to the distri-
bution reported for the Brazilian Black popu-
lation (19). A future extensive study may
clarify the influence of haplotype on γ chain
production stimulated with HU.
The predominant γ chain synthesis in-
duced by HU probably contributes to a milder
illness in SCD patients. The contributions of
Aγ and Gγ to the prevention of the sickling
process are apparently different. The pres-
ence of an alanine (Aγ) instead of a glycine
(Gγ) at position 136 of the γ chain interferes
with the interaction between γ chain and
sickle ß chain due to a reduced flexibility of
Aγ. Thus, Aγ is less effective than Gγ in pre-
venting the polymerization of the sickle ß
chain (20).
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